论文部分内容阅读
HCVRNA阳性的丙型肝炎46例，均经临床和／或组织学确诊。治疗组24例用IFNa－nl或a－2b3×106IU，隔日一次；对照组22例用一般护肝药物。HCVRNA12周转阴率治疗组为83．3％，对照组为9．0％（P＜0．001）。ALT和AST复常率治疗组也优于对照组（P＜0．05）。随访观察满48周者治疗组15例中HCVRNA持续转阴11例（73．3％）．对照组5例均持续阳性。治疗组中5例做了Ⅰ～Ⅲ型HCV基因分型，结果均为Ⅱ型。同时对急、慢性丙型肝炎的发病过程和病理诊断作了讨论。
46 cases of HCVRNA-positive hepatitis C were diagnosed clinically and / or histologically. The treatment group 24 cases with IFNa-nl or a-2b3 × 106IU every other day; control group, 22 cases with general liver drug. The negative rate of HCV RNA was 83.3% in the treatment group and 9.0% in the control group (P <0.001). ALT and AST normalization rate of the treatment group is also superior to the control group (P <0.05). Follow-up observation of 48 weeks treatment group 15 cases of HCVRNA continued negative in 11 cases (73.3%). Control group, 5 cases were positive. In the treatment group, 5 cases of type Ⅰ ~ Ⅲ HCV genotyping were done, the results were type Ⅱ. At the same time, the pathogenesis and pathological diagnosis of acute and chronic hepatitis C were discussed.